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Dear Editor,
The ETV6 gene, previously known as TEL, is a member of
the ETS family of transcription factors located at 12p13. Its
role in leukemogenesis was initially estabilished as a fusion
partner to the PDGFR-beta gene in a case of chronic
myelomonocytic leukemia with t (5;12)(q33;p13) [1]. The
ETV6-ABL gene product has been demonstrated to have ty-
rosine kinase activity remarkably similar to that of BCR-ABL,
despite the fusion partners for ABL being completely different
[2]. Several studies proved the efficacy of imatinib for patients
with hypereosinophilic syndrome (HES) and chronic eosino-
philic leukemia (CEL), especially in those who express the
FIP1L1-PDGFRα fusion gene [3–5]. As development of re-
sistance or intollerance to Imatinib in these patients may par-
allel that seen in chronic myeloid leukemia (CML), the eval-
uation of second-generation tyrosine kinase inhibitors (TKIs),
such as nilotinib, has been reported [6]. However, to date, little
is known on long-term efficacy and safety of second-
generation TKIs after imatinib failure in patients with eosino-
philic neoplasms.
A 65-year-oldmalewas found to have hemoglobin 13.0 g/dL,
platelets 302×103/μL, leukocytes 16.7×103/μL, with 65 %
neutrophilis, 3 %metamyelocytes, 3 %myelocytes, 10 % eosin-
ophils, 8 % basophils, 8 % lymphocytes, and 3 % monocytes.
The physical exam was negative. Bone marrow biopsy and
aspirate were consistent with a chronic phase myeloproliferative
neoplasm (MPN). Karyotype was 46,XY,t(9;12)(q34;p12); mo-
lecular analysis was negative for BCR/ABL and for rearrange-
ments involving PDGFRα andβ and FIP1L1 gene, while show-
ing a fusion between ETV6 and ABL genes.
The patient was enrolled in a protocol testing imatinib for
HES, starting in May 2005 at a dose of 100 mg daily, with
weekly dose escalation up to 400 mg/day. The patient attained
a complete hematologic response (CHR) at 1 month and a
complete cytogenetic response (CCyR) at 6 months. In Janu-
ary 2006, the patient complained an olfactory dysfunction
(dysosmia). An ear, nose, and throat (ENT) visit and central
nervous system RMN scan were negative; so supposing a
possible imatinib toxicity, the drug was stopped with a slight
improvement of olfactory function. There was a progressive
increase in eosinophil count; so in June 2006, imatinib was
restarted at 100 mg daily and progressively increased up to
400 mg, at which dose dysosmia recurred. In December 2006,
while receiving imatinib 400 mg, despite persistent olfactory
dysfunction, the patient lost CHR. To investigate imatinib
resistance, a mutational study of ABL kinase domain was
performed, without evidence of any mutation. In October
2007, the patient started nilotinib 400 mg twice a day. The
patient attained CHR within 2 weeks and regained CCyR
and molecular remission at 6 months that were confirmed at
the 12 months of therapy and at all the molecular testing per-
formed thereafter. Five years after initiation of nilotinib, the
patient developed signs of peripheral arterial occlusive disease
(PAOD) of the lower limbs that required angioplasty and sur-
gical treatment of the skin lesions. Nilotinib was reduced to
400 mg/day. In June 2014, almost 7 years from nilotinib start;
and while in confirmed complete molecular remission, the
patient complained of abdominal pain and weight loss. An
abdominal CT scan revealed a pancreatic carcinoma that
caused the patient’s death in September 2014.
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The chronic MPNs with associated eosinophilia are largely
linked to constitutively active cellular TKs that drive the clon-
al cell proliferation. The clinical significance of the identifica-
tion of such mutant kinases is their susceptibility to molecu-
larly targeted small-molecule inhibitors, which frequently
constitute a very effective treatment for these patients [3, 4].
We describe the case of a patient with atypical MPN with
ins(9;12)(q34;p13p13), producing an ETV6-ABL gene rear-
rangement. ETV6 is the only non-BCR fusion partner for
ABL reported to date, and it is thought to have TK activity
similar to BCR/ABL. In the last years, few case reports fo-
cused on the efficacy of imatinib in chronic-phase MPNs and
ETV6-ABL rearrangement, with cytogenetic and molecular
remissions but short follow-up [5, 7]. Our patient had an ex-
cellent response to imatinib though complicated by an unusual
olfactory toxicity (dysosmia) that, to the best of our knowl-
edge, has never been reported with imatinib. However, after
about 14 months of therapy, our patient experienced hemato-
logic and cytogenetic relapse, suggesting that TK inhibitory
effect of imatinib is therapeutically useful but not enough to
induce a long-term complete remission. As we did not docu-
ment any ABL TK domain mutation, like in other cases re-
ported to date, mechanism of imatinib resistance remains
unknown.
Only Nand et al. reported on a patient with ETV6-ABL-
positive MPN in chronic phase achieving CCyR on imatinib,
experiencing after 17 months cytogenetic relapse and
attaining with nilotinib a second CCyR, lasting 11 months at
the time of writing [6]. Our case displayed early (i.e., within
6 months) complete cytogenetic and molecular responses that
lasted for more than 6 years. Albeit its efficacy, nilotinib is
known to be associated with higher incidence of pancreatic
and metabolic abnormalities [8, 9] and, more recently, with a
significant incidence of progressive PAOD [10]. In line
with this, after 5 years of nilotinib, our patient progres-
sively develops signs of PAOD that required revasculari-
zation and dose reduction. Of note, at the time of nilotinib
start, the patients had no current risk factors for PAOD
except for age (68 years); during nilotinib therapy, the
patient developed a mild diabetes mellitus treated with
metformin with excellent glycemic control.
In summary, ETV6-ABL-positive eosinophilic MPN is a
rare clinical entity that, in chronic phase, often displays a
transient response to imatinib. Nilotinib therapy seems effec-
tive, also granting deep and durable response, but several is-
sues remain on drug’s long-term safety. Similar cases deserve
to be reported to allow further understanding of their molecu-
lar basis, disease history, and response to TKI therapy.
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